AstraZeneca foregoes early settlement of Japan Iressa legal cases
This article was originally published in Scrip
AstraZeneca has decided not to accept a court-proposed settlement in Japan in legal cases relating to side-effects during the use of its lung cancer drug Iressa (gefitinib).
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.